Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
RBD-4059 by Suzhou Ribo Life Sciences for Thromboembolism: Likelihood of Approval
RBD-4059 is under clinical development by Suzhou Ribo Life Sciences and currently in Phase I for Thromboembolism. According to GlobalData,...